Cell therapy continues to mature as a transformative therapeutic modality, with growing momentum around next-generation approaches such as in vivo CAR therapies, alongside continued evolution of ex vivo platforms. In this Cell Therapy January 2026 Landscape Review, Beacon by Hanson Wade delivers a data-driven analysis of how the global cell therapy ecosystem has evolved — and where it is heading next.
In this expert-led webinar, attendees will explore year-on-year growth across cell therapy assets, trials, companies, and partnerships, alongside the scientific, clinical, and commercial strategies defining success. From multi-target and in vivo CAR design to preconditioning approaches, regulatory momentum, and high-value M&A, this session provides actionable intelligence to support informed decision-making throughout 2026.
Key Highlights:
- Cell Therapy YoY growth:
Highlighting progression and stabilization in cell therapy assets, trials, deals, and companies - Multi-CAR target analysis:
Mapping prevalent target combinations in dual-targeted, tri-targeted and quad-targeted CAR therapies - Preconditioning analysis:
Evaluating the presence and absence of preconditioning regimens in clinical trials - Mergers & Acquisitions:
Reviewing the highest value deals from prominent players in 2025 - Regulatory Announcements:
An overview of the recent submissions, designations and approvals from regulatory agencies - Future of Cell Therapy:
Insights into armoring and in vivo CAR, as well as assets to watch in 2026
About the Speaker:
Safia Abdi is a Research Analyst for the Cell Therapy module at Beacon by Hanson Wade. She holds a BSc in Biomedical Sciences from Brunel University London and brings a strong haematology background from her previous role as an Associate Practitioner at St George’s Hospital, London.
Safia applies deep clinical understanding and rigorous analytical expertise to deliver comprehensive intelligence on cell therapy development across the preclinical, clinical, and commercial landscape. Her work supports strategic decision-making for biopharma leaders navigating the rapidly evolving cell therapy space.
Register now to hear Safia’s expert perspective and gain a forward-looking view of the cell therapy landscape in 2026.
Webinar Leaders
Dr. William Sanders
Global Vice President of Chemical Development Operations at Veranova
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
